StreetInsider.com News Articles

Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update

Mon, 01 Jun 2026 17:00:00 -0400

All dollar amounts reflected in Canadian dollars unless otherwise stated.

VANCOUVER, British Columbia, June 01, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced its financial results for the three months ended March 31, 2026 (“Q1 2026”), and provided an update on recent corporate developments.

Q1 2026 Financial Highlights

Research and development (R&D) expenses of $1,031,556, up from $885,594 in Q1 2025, reflecting expanded chemistry, AI research, and contract research activity supporting the advancement of the Company’s

Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update

Mon, 01 Jun 2026 17:00:00 -0400

All dollar amounts reflected in Canadian dollars unless otherwise stated.

Q1 2026 Financial Highlights

Research and development (R&D) expenses of $1,031,556, up from $885,594 in Q1 2025, reflecting expanded chemistry, AI research, and contract research activity supporting the advancement of the Company’s

Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update

Mon, 01 Jun 2026 17:00:00 -0400

All dollar amounts reflected in Canadian dollars unless otherwise stated.

Q1 2026 Financial Highlights

Research and development (R&D) expenses of $1,031,556, up from $885,594 in Q1 2025, reflecting expanded chemistry, AI research, and contract research activity supporting the advancement of the Company’s

Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update

Mon, 01 Jun 2026 17:00:00 -0400

All dollar amounts reflected in Canadian dollars unless otherwise stated.

Q1 2026 Financial Highlights

Research and development (R&D) expenses of $1,031,556, up from $885,594 in Q1 2025, reflecting expanded chemistry, AI research, and contract research activity supporting the advancement of the Company’s

Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update

Mon, 01 Jun 2026 17:00:00 -0400

All dollar amounts reflected in Canadian dollars unless otherwise stated.

Q1 2026 Financial Highlights

Research and development (R&D) expenses of $1,031,556, up from $885,594 in Q1 2025, reflecting expanded chemistry, AI research, and contract research activity supporting the advancement of the Company’s

Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update

Mon, 01 Jun 2026 17:00:00 -0400

All dollar amounts reflected in Canadian dollars unless otherwise stated.

Q1 2026 Financial Highlights

Research and development (R&D) expenses of $1,031,556, up from $885,594 in Q1 2025, reflecting expanded chemistry, AI research, and contract research activity supporting the advancement of the Company’s

Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update

Mon, 01 Jun 2026 17:00:00 -0400

All dollar amounts reflected in Canadian dollars unless otherwise stated.

Q1 2026 Financial Highlights

Research and development (R&D) expenses of $1,031,556, up from $885,594 in Q1 2025, reflecting expanded chemistry, AI research, and contract research activity supporting the advancement of the Company’s

Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update

Mon, 01 Jun 2026 17:00:00 -0400

All dollar amounts reflected in Canadian dollars unless otherwise stated.

Q1 2026 Financial Highlights

Research and development (R&D) expenses of $1,031,556, up from $885,594 in Q1 2025, reflecting expanded chemistry, AI research, and contract research activity supporting the advancement of the Company’s

Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update

Mon, 01 Jun 2026 17:00:00 -0400

All dollar amounts reflected in Canadian dollars unless otherwise stated.

Q1 2026 Financial Highlights

Research and development (R&D) expenses of $1,031,556, up from $885,594 in Q1 2025, reflecting expanded chemistry, AI research, and contract research activity supporting the advancement of the Company’s

Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update

Mon, 01 Jun 2026 17:00:00 -0400

All dollar amounts reflected in Canadian dollars unless otherwise stated.

Q1 2026 Financial Highlights

Research and development (R&D) expenses of $1,031,556, up from $885,594 in Q1 2025, reflecting expanded chemistry, AI research, and contract research activity supporting the advancement of the Company’s

Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update

Mon, 01 Jun 2026 17:00:00 -0400

All dollar amounts reflected in Canadian dollars unless otherwise stated.

Q1 2026 Financial Highlights

Research and development (R&D) expenses of $1,031,556, up from $885,594 in Q1 2025, reflecting expanded chemistry, AI research, and contract research activity supporting the advancement of the Company’s

Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update

Mon, 01 Jun 2026 17:00:00 -0400

All dollar amounts reflected in Canadian dollars unless otherwise stated.

Q1 2026 Financial Highlights

Research and development (R&D) expenses of $1,031,556, up from $885,594 in Q1 2025, reflecting expanded chemistry, AI research, and contract research activity supporting the advancement of the Company’s

Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update

Mon, 01 Jun 2026 17:00:00 -0400

All dollar amounts reflected in Canadian dollars unless otherwise stated.

Q1 2026 Financial Highlights

Research and development (R&D) expenses of $1,031,556, up from $885,594 in Q1 2025, reflecting expanded chemistry, AI research, and contract research activity supporting the advancement of the Company’s

Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update

Mon, 01 Jun 2026 17:00:00 -0400

All dollar amounts reflected in Canadian dollars unless otherwise stated.

Q1 2026 Financial Highlights

Research and development (R&D) expenses of $1,031,556, up from $885,594 in Q1 2025, reflecting expanded chemistry, AI research, and contract research activity supporting the advancement of the Company’s

Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update

Thu, 30 Apr 2026 17:10:00 -0400

VANCOUVER, British Columbia, April 30, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7J0), a biopharmaceutical company advancing next-generation cancer therapies through artificial intelligence (AI)-powered drug discovery, today announced its financial results for the fourth quarter and fiscal year ended December 31, 2025, and provided a corporate update.

As Rakovina enters 2026, the Company is advancing its three primary drug discovery programs toward key value-creating milestones. For kt-5000, lead optimization continues with Variational AI, with lead candidate selection and IND-enabling studies targeted for the second half of 2026. For kt-3283, in

Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update

Thu, 30 Apr 2026 17:10:00 -0400

Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update

Thu, 30 Apr 2026 17:10:00 -0400

Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update

Thu, 30 Apr 2026 17:10:00 -0400

Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update

Thu, 30 Apr 2026 17:10:00 -0400

Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update

Thu, 30 Apr 2026 17:10:00 -0400

Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update

Thu, 30 Apr 2026 17:10:00 -0400

Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update

Thu, 30 Apr 2026 17:10:00 -0400

Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update

Thu, 30 Apr 2026 17:10:00 -0400

Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update

Thu, 30 Apr 2026 17:10:00 -0400

Rakovina Therapeutics Inc. Announces 2025 Financial Results and Provides Corporate Update

Thu, 30 Apr 2026 17:10:00 -0400